Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DFV 890

Next Previous
X
Search
Drug Profile

DFV 890

Alternative Names: DFV890; DV-890; IFM-2427

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IFM Tre
  • Developer Novartis
  • Class Anti-inflammatories; Hepatoprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; COVID-19 pneumonia; Cryopyrin-associated periodic syndromes; Osteoarthritis; SARS-CoV-2 acute respiratory disease
  • Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • No development reported Inflammation

Most Recent Events

  • 16 Feb 2024 Phase-II clinical trials in Coronary disorders in Canada (PO) (NCT06097663)
  • 16 Feb 2024 Phase-II clinical trials in Coronary disorders in Germany (PO) (NCT06097663)
  • 25 Oct 2023 Novartis Pharmaceuticals plans a phase II trial for Coronary disorders (PO) in December 2023 (NCT06097663)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top